Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,004
datasets available to search
ShareScore release 0.9.0
Dataset results
1,004 results for “neuroendocrine”
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
ClinicalTrials.gov study NCT01524783. IPD Sharing: YES. Countries: 25. Publications: 5.
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model
ClinicalTrials.gov study NCT04051320. IPD Sharing: YES. Countries: 1. Publications: 98.
Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining
<p>Neuroendocrine neoplasms (NENs) are clinically diverse and incompletely characterized cancers that are challenging to classify. MicroRNAs (miRNAs) are small regulatory RNAs that can be used to classify cancers. Recently, a morphology-based classification framework for evaluating NENs from different anatomic sites was proposed by experts, with the requirement of improved molecular data integration. Here, we compiled 378 miRNA expression profiles to examine NEN classification through comprehensive miRNA profiling and data mining. Following data preprocessing, our final study cohort included 221 NEN and 114 non-NEN samples, representing 15 NEN pathological types and five site-matched non-NEN control groups. Unsupervised hierarchical clustering of miRNA expression profiles clearly separated NENs from non-NENs. Comparative analyses showed that miR-375 and miR-7 expression is substantially higher in NEN cases than non-NEN controls. Correlation analyses showed that NENs from diverse anatomic sites have convergent miRNA expression programs, likely reflecting morphologic and functional similarities. Using machine learning approaches, we identified 17 miRNAs to discriminate 15 NEN pathological types and subsequently constructed a multi-layer classifier, correctly identifying 217 (98%) of 221 samples and overturning one histologic diagnosis. Through our research, we have identified common and type-specific miRNA tissue markers and constructed an accurate miRNA-based classifier, advancing our understanding of NEN diversity.</p>
Data for: Neuroendocrine gene expression coupling of interoceptive bacterial food cues to foraging behavior of C. elegans
<p>Animal internal state is modulated by nutrient intake, resulting in behavioral responses to changing food conditions. The neural mechanisms by which internal states are generated and maintained are not well understood. Here, we show that in the nematode <em>Caenorhabditis elegans, </em>distinct cues from bacterial food – interoceptive signals from the ingestion of bacteria and gustatory molecules sensed from nearby bacteria – act antagonistically on the expression of the neuroendocrine TGF-beta ligand DAF-7 from the ASJ pair of sensory neurons to modulate foraging behavior. A positive-feedback loop dependent on the expression of <em>daf-7 </em>from the ASJ neurons acts to promote transitions between roaming and dwelling foraging states and influence the persistence of roaming states. SCD-2, the <em>C. elegans </em>ortholog of mammalian Anaplastic Lymphoma Kinase (ALK), which has been implicated in the central control of metabolism of mammals, functions in the AIA interneurons to regulate foraging behavior and cell-non-autonomously control the expression of DAF-7 from the ASJ neurons. Our data establish how a dynamic neuroendocrine <em>daf-7 </em>expression feedback loop regulated by SCD-2 functions to couple sensing and ingestion of bacterial food to foraging behavior. We further suggest that this neuroendocrine feedback loop underlies previously characterized exploratory behaviors in <em>C. elegans</em>. Our data suggest that the expression of <em>daf-7</em> from the ASJ neurons contributes to and is correlated with an internal state of "unmet need" that regulates exploratory foraging behavior in response to bacterial cues in diverse physiological contexts.</p>
Supplementary material: CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer
<p>Castration-resistant prostate cancer (CRPC) is associated with resistance to androgen deprivation therapy, and an increase in the population of neuroendocrine (NE) differentiated cells. It is hypothesized that NE differentiated cells secrete neuropeptides that support androgen-independent tumor growth and induce aggressiveness of adjacent proliferating tumor cells through a paracrine mechanism. The cytochrome b561 (<em>CYB561</em>) gene, which codes for a secretory vesicle transmembrane protein, is constitutively expressed in NE cells and highly expressed in CRPC. CYB561 is involved in the α-amidation-dependent activation of neuropeptides and contributes to regulating iron metabolism which is often dysregulated in cancer. These findings led us to hypothesize that CYB561 may be a key player in the NE differentiation process that drives the progression and maintenance of the highly aggressive NE phenotype in CRPC. In our study, we found that <em>CYB561</em> expression is upregulated in metastatic and NE prostate cancer (NEPC) tumors and cell lines compared to normal prostate epithelia and that its expression is independent of androgen regulation. Knockdown of <em>CYB561</em> in androgen-deprived LNCaP cells dampened NE differentiation potential and transdifferentiation-induced increase in iron levels. In NEPC PC-3 cells, depletion of CYB561 reduced the secretion of growth-promoting factors, lowered intracellular ferrous iron concentration, and mitigated the highly aggressive nature of these cells in complementary assays for cancer hallmarks. These findings demonstrate the role of CYB561 in facilitating transdifferentiation and maintenance of NE phenotype in CRPC through its involvement in neuropeptide biosynthesis and iron metabolism pathways.</p>
Molecular deciphering of primary liver neuroendocrine neoplasms confirms its distinct existence with foregut-like profile
<p>Isolated hepatic localizations of neuroendocrine tumors (NETs) are generally considered as metastatic NETs of unknown primary but could correspond to primary hepatic NETs (PHNETs), a poorly explored entity. We aimed to describe the clinicopathological and molecular features of PHNETs and compare them with other primary NETs. We assembled a retrospective cohort of patients managed for hepatic localization of NET without extra-hepatic primary tumor after exhaustive clinical, imaging and immunohistochemical characterization. We performed whole-exome sequencing with mutational and copy number analysis. Transcriptomic profiles were compared to pancreatic (n=31), small-bowel (n=22) and lung (n=15) NETs using principal component analysis, unsupervised clustering and gene-set enrichment analysis.Among 27 screened patients, 16 had PHNET (solitary tumor in 63%, median size 11 cm, G2 NETs in 81%) following clinical and pathological review. DNA analyses showed “foregut-like” genomic profiles with frequent alterations in pathways of Fanconi DNA repair (75%), histone modifiers (58%), adherens junctions (58%) and cell cycle control (50%). The most frequently involved genes were <em>KMT2A</em> (58%), <em>ATM</em> (42%), <em>CDH1</em>, <em>CDKN2C</em>, <em>FANCF</em> and <em>MEN1</em> (33% each). Transcriptomic analyses showed that PHNETs clustered closer to foregut (pancreatic, lung) NETs than to midgut (small-bowel) NETs, while remaining a distinct entity with specific profile. Assessment of potentially predictive biomarkers suggested efficacy of treatments usually active in foregut NETs. In conclusion, PHNETs display a foregut-like molecular profile distinct from other types of NETs, with recurrent molecular alterations. Upon exhaustive work-up to exclude unrecognized primary tumor, PHNETs should not be considered metastatic NETs from an unknown primary.</p>
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
ClinicalTrials.gov study NCT02698410. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
ClinicalTrials.gov study NCT02939651. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
ClinicalTrials.gov study NCT04452292. IPD Sharing: NO. Countries: 1. Publications: 1.
Leptin in Human Energy and Neuroendocrine Homeostasis
ClinicalTrials.gov study NCT00265980. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
ClinicalTrials.gov study NCT00607113. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
ClinicalTrials.gov study NCT03070301. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
ClinicalTrials.gov study NCT04702737. IPD Sharing: YES. Countries: 9. Publications: 1.
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
ClinicalTrials.gov study NCT03724409. IPD Sharing: YES. Countries: 1. Publications: 1.
Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy
ClinicalTrials.gov study NCT01201863. IPD Sharing: Not stated. Countries: 1. Publications: 1.
PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
ClinicalTrials.gov study NCT03179410. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
ClinicalTrials.gov study NCT01253161. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
ClinicalTrials.gov study NCT02678780. IPD Sharing: Not stated. Countries: 4. Publications: 2.
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
ClinicalTrials.gov study NCT02075606. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Phase 2 Study of ONC201 in Neuroendocrine Tumors
ClinicalTrials.gov study NCT03034200. IPD Sharing: NO. Countries: 1. Publications: 8.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.